Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers

Bock, Muriel De; Béguin, Yves; Leprince, Pierre; Willems, Évelyne; Baron, Frédéric; Deroyer, Céline; Seidel, Laurence; Cavalier, Étienne; Seny, Dominique de; Malaise, Michel; Gothot, André; Merville, Marie‐Paule; Fillet, Marianne

doi:10.1016/j.talanta.2014.03.017

Cited by 9 publications

(8 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From an early diagnostic perspective, it would be ideal if subjects at risk for high-grade GVHD could be identified during the activation phase to fortify immunosuppressive therapy. Several candidate blood biomarkers have shown promise for early detection of aGVHD including a panel of proteomic blood biomarkers capable of diagnosis approximately 15 days before definitive diagnosis (10). Cellular biomarkers of aGVHD in the blood have also been explored.…”

Section: Discussionmentioning

confidence: 99%

“…Invasive endoscopic guided biopsy (often from liver or GI tract) are required to confirm an aGVHD(4), but bleeding tendency and critical illness associated with HCT make it near impossible to perform these procedures. Blood biomarkers are under active investigation but to date no biomarker has been validated for early aGVHD diagnosis (10,11). These critical issues dramatically delay the onset and effectiveness of potentially life-saving pre-emptive or early treatment interventions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant

et al. 2017

View full text Add to dashboard Cite

A major barrier to successful use of allogeneic hematopoietic cell transplantation is acute graft-versus-host disease (aGVHD), a devastating condition that arises when donor T cells attack host tissues. With current technologies, aGVHD diagnosis is typically made after end-organ injury and often requires invasive tests and tissue biopsies. This impacts patient prognosis as treatments are dramatically less effective at late disease stages. Here we show that a novel positron emission tomography (PET) radiotracer, 2′-deoxy-2′-[18F]fluoro-9-β-D-arabinofuranosylguanine ([18F]F-AraG), targeted towards two salvage kinase pathways preferentially accumulates in activated primary T cells. [18F]F-AraG PET imaging of a murine aGVHD model enabled visualization of secondary lymphoid organs harboring activated donor T cells prior to clinical symptoms. Tracer biodistribution in healthy humans showed favorable kinetics. This new PET strategy has great potential for early aGVHD diagnosis, enabling timely treatments and improved patient outcomes. [18F]F-AraG may be useful for imaging activated T cells in various biomedical applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In contrast, the role of SAA4, which was shown to be differentially expressed in this study, is not well understood in human disease. SAA4 is expressed in graft-versus-host disease (GVHD) and epithelial ovarian tumors [ 37 , 38 ]; however, to the best of our knowledge, this is the first report describing SAA4 expression in RA. Moreover, we found that SAA4 was differentially expressed in RA, as detected by LC-MS/MS analysis of prescreening serum and validated by ELISA.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of SAA4 as a Rheumatoid Arthritis Prescreening Marker by Liquid Chromatography Tandem-mass Spectrometry

Seok

Lee

et al. 2017

Molecules

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic autoimmune disease that progresses into systemic inflammation and joint deformity. RA diagnosis is a complicated procedure, and early diagnostic methods are insufficient. Therefore, in this study, we attempted to identify new markers to improve the accuracy of RA prescreening. e identified differentially expressed proteins (DEPs) by using liquid chromatography tandem-mass spectrometry in health-prescreening sera with high rheumatoid factor (RF) values, and compared the findings with those from sera with normal RF values. We identified 93 DEPs; of these, 36 were upregulated, and 57 were downregulated in high-RF sera. Pathway analysis revealed that these DEPs were related to immune responses. Additionally, four DEPs were statistically analyzed by proteomic analysis; of these, SAA4 was significantly validated in individual enzyme-linked immunosorbent assays. Moreover, SAA4 was significantly upregulated in RA patients (n = 40, 66.43 ± 12.97 ng/mL) compared with normal controls (n = 40, 4.79 ± 0.95 ng/mL) and had a higher area under the curve than C-reactive protein. Thus, we identified SAA4 as a protein that was positively correlated with RF and RA. SAA4 may represent a novel prescreening marker for the diagnosis of RA.

show abstract

“…Apolipoproteins are high abundance serum proteins situated on the surface of lipoprotein particles that transport highly hydrophobic lipids. Current evidence suggests apolipoprotein A1 (ApoA-1) is a potential diagnostic biomarker for coronary heart disease risk [ 1 , 2 ]. Furthermore, the risk of coronary heart disease is strongly associated with increased adiposity, which can be further increased by smoking behavior [ 3 , 4 ].…”

mentioning

confidence: 99%

Serum Apolipoprotein A-1 Quantification by LC–MS with A Silac Internal Standard Reveals Reduced Levels in Smokers

et al. 2015

View full text Add to dashboard Cite

Background Absolute quantification of protein biomarkers such as serum apolipoprotein A1 by both immunoassays and LC–MS can provide misleading results. Results Recombinant ApoA-1 internal standard was prepared using stable isotope labeling by amino acids in cell culture with [13C615N2]-lysine and [13C915N1]-tyrosine in human cells. A stable isotope dilution LC–MS method for serum ApoA-1 was validated and levels analyzed for 50 nonsmokers and 50 smokers. Conclusion The concentration of ApoA-1 in nonsmokers was 169.4 mg/dl with an 18.4% reduction to 138.2 mg/dl in smokers. The validated assay will have clinical utility for assessing effects of smoking cessation and therapeutic or dietary interventions in high-risk populations.

show abstract

Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers

Cited by 9 publications

References 62 publications

A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant

A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant

Identification and Validation of SAA4 as a Rheumatoid Arthritis Prescreening Marker by Liquid Chromatography Tandem-mass Spectrometry

Serum Apolipoprotein A-1 Quantification by LC–MS with A Silac Internal Standard Reveals Reduced Levels in Smokers

Contact Info

Product

Resources

About